Besides, in IDH1/2-mutant AML, the differentiation-inducing effects of IDH inhibitors (e.g., ivosidenib, enasidenib) can be potentiated by co-treatment with hypomethylating agents. The gene discussed is IDH2; the disease is acute myeloid leukemia.